Embed

Academic

Authors

David C. Dalgarno

David C. Dalgarno,Massachusetts Institute of Technology,Cell Biology,Pharmacology,Oncology

Edit

David C. Dalgarno

Massachusetts Institute of Technology

Publications: 20 | Citations: 428

Fields: Cell Biology, Pharmacology, Oncology

Collaborated with 131 co-authors from 1993 to 2011 | Cited by 1411 authors

Cumulative Annual

Sort by:

Publications (20)

BibTeX | RIS | RefWorks Download

Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients

, , , , , ,

Journal: Journal of Antibiotics - J ANTIBIOT , vol. 64, no. 9, pp. 649-654, 2011

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance (Citations: 30)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=36524128&selfId1=10841148&selfId2=0&maxNumber=12&query=

Journal: Cancer Cell , vol. 16, no. 5, pp. 401-412, 2009

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance (Citations: 33)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=15175815&selfId1=10841148&selfId2=0&maxNumber=12&query=

Journal: Proceedings of The National Academy of Sciences - PNAS , vol. 103, no. 24, pp. 9244-9249, 2006

Src Inhibitors in Metastatic Bone Disease (Citations: 12)

, , , , , , , , , ,

Journal: Clinical Cancer Research - CLIN CANCER RES , vol. 12, no. 20, pp. 6291s-6295s, 2006

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit (Citations: 22)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=7004546&selfId1=10841148&selfId2=0&maxNumber=12&query=

Published in 2005.

Sort by:

Citations (428 times by 356 publications)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

Journal: Leukemia , vol. 26, no. 2, pp. 214-224, 2012

Transient Protein-Protein Interaction of the SH3Peptide Complex via Closely Located Multiple Binding Sites

Journal: PLOS One , vol. 7, no. 3, 2012

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition (Citations: 2)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=54491473&selfId1=10841148&selfId2=0&maxNumber=12&query=

Journal: Nature , vol. 473, no. 7347, pp. 384-388, 2011

Allosteric Interactions between the Myristate and ATP-Site of the Abl Kinase (Citations: 3)

, , , ,

Journal: PLOS One , vol. 6, no. 1, 2011

PVSS23. PAD patients who undergo more invasive revascularization procedures are more likely to decrease or quit smoking

, , , , ,

Journal: Journal of Vascular Surgery - J VASC SURG , vol. 53, no. 6, pp. 15S-15S, 2011

Comments

Co-authors (131)

Journals (13)

Keywords (91)

David C. Dalgarno,Massachusetts Institute of Technology,Cell Biology,Pharmacology,Oncology

Publications (20)

BibTeX | RIS | RefWorks Download

Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance (Citations: 30)

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance (Citations: 33)

Src Inhibitors in Metastatic Bone Disease (Citations: 12)

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit (Citations: 22)

Citations (428 times by 356 publications)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

Transient Protein-Protein Interaction of the SH3Peptide Complex via Closely Located Multiple Binding Sites

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition (Citations: 2)

Allosteric Interactions between the Myristate and ATP-Site of the Abl Kinase (Citations: 3)

PVSS23. PAD patients who undergo more invasive revascularization procedures are more likely to decrease or quit smoking


	View FAQ about top research areas and Fields of study

Co-authors (131)

Journals (13)

Keywords (91)

David C. Dalgarno,Massachusetts Institute of Technology,Cell Biology,Pharmacology,Oncology

Publications (20) BibTeX | RIS | RefWorks Download

Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance (Citations: 30)

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance (Citations: 33)

Src Inhibitors in Metastatic Bone Disease (Citations: 12)

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit (Citations: 22)

Citations (428 times by 356 publications)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

Transient Protein-Protein Interaction of the SH3Peptide Complex via Closely Located Multiple Binding Sites

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition (Citations: 2)

Allosteric Interactions between the Myristate and ATP-Site of the Abl Kinase (Citations: 3)

PVSS23. PAD patients who undergo more invasive revascularization procedures are more likely to decrease or quit smoking

Publications (20)

BibTeX | RIS | RefWorks Download